418 related articles for article (PubMed ID: 15720454)
21. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Priori SG
Prog Cardiovasc Dis; 2008; 51(1):23-30. PubMed ID: 18634915
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
23. [Catecholaminergic polymorphic ventricular tachycardia].
Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
[TBL] [Abstract][Full Text] [Related]
24. Catecholaminergic polymorphic ventricular tachycardia.
Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
[TBL] [Abstract][Full Text] [Related]
25. Cardiac ryanodine receptor function and regulation in heart disease.
Lehnart SE; Wehrens XH; Kushnir A; Marks AR
Ann N Y Acad Sci; 2004 May; 1015():144-59. PubMed ID: 15201156
[TBL] [Abstract][Full Text] [Related]
26. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.
Mohamed U; Napolitano C; Priori SG
J Cardiovasc Electrophysiol; 2007 Jul; 18(7):791-7. PubMed ID: 17578347
[TBL] [Abstract][Full Text] [Related]
27. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
28. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
29. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction.
George CH; Jundi H; Walters N; Thomas NL; West RR; Lai FA
Circ Res; 2006 Jan; 98(1):88-97. PubMed ID: 16339485
[TBL] [Abstract][Full Text] [Related]
30. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia.
Marjamaa A; Hiippala A; Arrhenius B; Lahtinen AM; Kontula K; Toivonen L; Happonen JM; Swan H
J Cardiovasc Electrophysiol; 2012 Feb; 23(2):194-9. PubMed ID: 21954897
[TBL] [Abstract][Full Text] [Related]
31. Role of ryanodine receptor mutations in cardiac pathology: more questions than answers?
Thomas NL; George CH; Lai FA
Biochem Soc Trans; 2006 Nov; 34(Pt 5):913-8. PubMed ID: 17052226
[TBL] [Abstract][Full Text] [Related]
32. S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
Zhabyeyev P; Hiess F; Wang R; Liu Y; Wayne Chen SR; Oudit GY
Can J Cardiol; 2013 Aug; 29(8):993-6. PubMed ID: 23498838
[TBL] [Abstract][Full Text] [Related]
33. A novel mutation (Arg169Gln) of the cardiac ryanodine receptor gene causing exercise-induced bidirectional ventricular tachycardia.
Hsueh CH; Weng YC; Chen CY; Lin TK; Lin YH; Lai LP; Lin JL
Int J Cardiol; 2006 Apr; 108(2):276-8. PubMed ID: 16517285
[TBL] [Abstract][Full Text] [Related]
34. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak.
Lehnart SE; Wehrens XH; Laitinen PJ; Reiken SR; Deng SX; Cheng Z; Landry DW; Kontula K; Swan H; Marks AR
Circulation; 2004 Jun; 109(25):3208-14. PubMed ID: 15197150
[TBL] [Abstract][Full Text] [Related]
35. Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features.
Bhuiyan ZA; van den Berg MP; van Tintelen JP; Bink-Boelkens MT; Wiesfeld AC; Alders M; Postma AV; van Langen I; Mannens MM; Wilde AA
Circulation; 2007 Oct; 116(14):1569-76. PubMed ID: 17875969
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
37. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
Heiner JD; Bullard-Berent JH; Inbar S
Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
[TBL] [Abstract][Full Text] [Related]
38. [Catecholaminergic polymorphic ventricular tachycardia is a rare inherited heart disease].
Holst AG; Tfelt-Hansen J; Olesen MS; Theilade J; Winkel BG; Christensen AH; Bundgaard H; Haunsø S; Svendsen JH
Ugeskr Laeger; 2010 Aug; 172(31):2140-4. PubMed ID: 20670590
[TBL] [Abstract][Full Text] [Related]
39. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia.
Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH
Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584
[TBL] [Abstract][Full Text] [Related]
40. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.
de la Fuente S; Van Langen IM; Postma AV; Bikker H; Meijer A
Pacing Clin Electrophysiol; 2008 Jul; 31(7):916-9. PubMed ID: 18684293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
